Skip to content

Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02301858
Enrollment
100
Registered
2014-11-26
Start date
2013-12-31
Completion date
2025-12-31
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Metastases, Primary Tumor

Keywords

molecular pathology, functional genomics, lung cancer, primary tumor, metastases

Brief summary

The project aims to compare the histopathological and molecular characteristics of tumour tissue from metastases with similar analyses of the primary tumour in the lung, where it is available. The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples.

Detailed description

The investigators want to make genome analysis of tissue samples. This involves analysing the RNA, DNA methylation, for example in cancer cells. This will provide information regarding somatic changes in cancer cells, such as mutations. All of the investigators analysis will be cancer-focused, with the goal of increasing understanding of the heterogeneity. The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples. This will then be the miRNA, RNA expression or protein expression in blood samples.

Interventions

GENETICGenome analysis of tissue samples.

Genome analysis of tissue samples.

Sponsors

Oslo University Hospital
CollaboratorOTHER
Janna Berg
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients with metastasizing lung cancer where further treatment is still applicable.

Exclusion criteria

* Terminal patients or patients in a reduced general condition with EGOC 3-4, i.e. patients who are confined to bed more than 50% of the day, with no clinical indication to perform sampling of the tumor and metastases. * Patients where further cancer treatment is no longer applicable. * Patients with cognitive impairment. * Patients with inaccessible metastases where sampling may cause distress to the patient and are at increased risk of complications.

Design outcomes

Primary

MeasureTime frameDescription
Comparing histopathological and molecular characteristics of tumour tissue from metastases with the primary tumour in the lung5 yearsWe will do profiling of the mRNA (messenger ribonucleic acid) expression of microRNA and perform single nucleotide polymorphism analysis of cancer tissue and compare the expression using statistical methods such as SAM (Significance analysis and microarrays), PAM (Prediction analysis of microarrays). In addition, we wish to perform specific genetic analysis of cancer-related genes. These will be made with available methods like sequencing or TaqMan assays for specific mutations. Blood samples will be analysed by microarray methods for RNA and microRNA in addition to serum analysis of proteins.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026